Kidney cancer and 2014: is innovation really over? - Wikidata - wikimedia - TriplyDB

Kidney cancer and 2014: is innovation really over?

Kidney cancer and 2014: is innovation really over?

http://www.wikidata.org/entity/Q38465870

about

Kidney cancer and 2014: is innovation really over?

http://www.wikidata.org/entity/Q38465870

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Kidney cancer and 2014: is innovation really over?

@en

type

label

Kidney cancer and 2014: is innovation really over?

@en

prefLabel

Kidney cancer and 2014: is innovation really over?

@en

P1433

Q38465870-14BDF092-7BEA-4963-A2D2-790F2CF9959F

P1476

Q38465870-81F182B0-517D-4940-B8ED-7E0565E7D87A

P2093

Q38465870-15B67D35-D2A0-414B-9476-BB939A03B27F

Q38465870-23492021-11EA-4E0A-BA89-16181404B4F8

P2860

Q38465870-093E58ED-2CD5-4015-A2BC-050CFAFFB396

Q38465870-0A5D1F42-8A10-4980-9357-82278B3C357F

Q38465870-0AF01EA4-7E8D-4E91-A076-438E5B36CFEB

Q38465870-0BF5A08A-DF9C-483F-BA4C-3E6529D0CCF5

Q38465870-1212C6D4-57B1-4680-84E9-AFFDF5A4F057

Q38465870-1B2C3336-DB67-4966-8168-9ACDDE061266

Q38465870-1D45B4E1-2A34-41D3-96CC-66AD2EABFD7D

Q38465870-2163AE7C-76A9-423A-BE47-DE81899C2E7E

Q38465870-2B83A50F-8B3C-4A8E-9553-F9B30EC13FB2

Q38465870-30DC72DF-C1C9-4E2C-B340-77ADFA27723C

P304

Q38465870-1EDE197D-5A9F-4AB3-8EC6-F29D5C120024

P31

Q38465870-99582996-6942-41B9-B03C-27381C3E127F

P356

Q38465870-1FBA2B73-7C0E-4139-ADC1-2B2E9285FAFF

P407

Q38465870-B534B50D-9626-48B3-BF0B-7620DBDF9F16

P433

Q38465870-0B3703DD-0E83-4CB9-A2B6-2B5286F9ECC2

P478

Q38465870-F1231A84-2AFB-4ED4-85BB-FD646536B2A2

P50

Q38465870-51897AEE-B189-468E-8EC6-AF0D48E75C85

Q38465870-AD116AF0-1FEA-4088-8FC8-099236A17DFB

P577

Q38465870-CF5488C2-349B-44ED-B90A-CB18AB8701B7

P5875

Q38465870-B65FD996-AA90-443A-B93E-020818B85197

P698

Q38465870-E6DA5DFF-5DDD-4E60-A0AE-00D09E98A0F8

P356

P1433

Future Oncology

P1476

Kidney cancer and 2014: is innovation really over?

@en

P2093

Alessandra Modena

http://www.w3.org/2001/XMLSchema#string

Chiara Ciccarese

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

An overview of the c-MET signaling pathway

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Adjuvant therapy for renal cell carcinoma: past, present, and future

P304

1437-1449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.15.37

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Giampaolo Tortora

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276067754

http://www.w3.org/2001/XMLSchema#string

P698

25952788

http://www.w3.org/2001/XMLSchema#string